# FDA Approves Generic Drug Application for Actavis Labs FL Inc Actavis Labs FL Inc received FDA approval for abbreviated new drug application (ANDA) 208959 on March 19, 2026, positioning the company to capture generic market share in a competitive pharmaceutical segment. The approval strengthens Actavis's portfolio and enables the manufacturer to compete on cost-effectiveness, potentially pressuring branded drug pricing while expanding its presence in the generics market.